Keros Therapeutics, Inc. (KROS)
11.32
+0.21
(+1.89%)
USD |
NASDAQ |
Sep 04, 16:00
11.31
-0.01
(-0.09%)
After-Hours: 20:00
Keros Therapeutics SG&A Expense (TTM) : 40.62M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.62M |
| March 31, 2026 | 46.50M |
| December 31, 2025 | 46.85M |
| September 30, 2025 | 45.77M |
| June 30, 2025 | 45.46M |
| March 31, 2025 | 40.94M |
| December 31, 2024 | 40.75M |
| September 30, 2024 | 39.19M |
| June 30, 2024 | 38.52M |
| March 31, 2024 | 37.36M |
| December 31, 2023 | 34.83M |
| September 30, 2023 | 32.82M |
| June 30, 2023 | 30.61M |
| March 31, 2023 | 29.26M |
| December 31, 2022 | 27.52M |
| Date | Value |
|---|---|
| September 30, 2022 | 26.46M |
| June 30, 2022 | 24.89M |
| March 31, 2022 | 23.10M |
| December 31, 2021 | 21.33M |
| September 30, 2021 | 18.91M |
| June 30, 2021 | 17.10M |
| March 31, 2021 | 15.09M |
| December 31, 2020 | 12.80M |
| September 30, 2020 | 9.18M |
| June 30, 2020 | 6.599M |
| March 31, 2020 | 3.603M |
| December 31, 2019 | 2.117M |
| September 30, 2019 | 2.117M |
| June 30, 2019 | 1.145M |
| March 31, 2019 | 0.491M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Incyte Corp. | 1.399B |
| Viking Therapeutics, Inc. | 50.70M |
| Nurix Therapeutics, Inc. | 57.01M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |